(15 days)
No
The summary describes an imaging accessory and its performance studies, with no mention of AI or ML technologies.
No
The device is described as a diagnostic tool for imaging the anterior segment of the eye and aiding in the assessment and management of diseases, which indicates a diagnostic rather than a therapeutic purpose.
Yes
The "Device Description" states that "The Spectralis HRA+OCT is a diagnostic device for imaging the human eye and for aiding in the assessment and management of various diseases of the posterior segment of the eye," and the Spectralis Anterior Segment Module is an accessory to this diagnostic device, extending its imaging capabilities to the anterior segment.
No
The device is described as an "accessory" to a hardware device (Spectralis HRA+OCT) and provides the "additional ability to image and examine the anterior segment of the eye using simultaneous OCT and infrared reflectance imaging". This indicates it is a hardware component that adds imaging capabilities, not a standalone software application.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In vitro diagnostics are tests performed on samples taken from the human body, such as blood, urine, or tissue, to detect diseases, conditions, or infections.
- Device Function: The Spectralis Anterior Segment Module is a diagnostic imaging device that directly images the anterior segment of the eye. It does not analyze samples taken from the body.
- Intended Use: The intended use is for "imaging the anterior segment of the eye," which is a direct imaging procedure, not an in vitro test.
- Anatomical Site: The anatomical site is the "Anterior segment of the eye," which is a part of the living body being imaged directly.
Therefore, the Spectralis Anterior Segment Module falls under the category of medical imaging devices, not in vitro diagnostics.
N/A
Intended Use / Indications for Use
The Spectralis Anterior Segment Module is an accessory to the Spectralis HRA+OCT, and is indicated for imaging the anterior segment of the eye.
Product codes
OBO, MYC
Device Description
The Spectralis Anterior Segment Module (Spectralis ASM) is an accessory to the Spectralis HRA+OCT device cleared under K101223. The Spectralis HRA+OCT is a diagnostic device for imaging the human eye and for aiding in the assessment and management of various diseases of the posterior segment of the eye. Addition of the Spectralis ASM provides the user the additional ability to image and examine the anterior segment of the eye using simultaneous OCT and infrared reflectance imaging with OCT B-scan lengths of 8 mm, 11 mm, and 16 mm. Available OCT scan patterns are single line scans and volume scans.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
simultaneous OCT and infrared reflectance imaging
Anatomical Site
anterior segment of the eye
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Side-by-side images of the anterior segment of the eye were compared between the Spectralis ASM and the predicate. Images from both eyes of 29 subjects (healthy eyes and eyes with pathology) were compared by an ophthalmologist using Spectralis ASM and RTVue, and equivalence between the images was concluded.
Summary of Performance Studies
Study Type: Bench Testing and Equivalence in Viewing the Anterior Segment (comparative study)
Sample Size: 29 subjects
Summary of Results: The Spectralis HRA+OCT has been tested according to IEC 60601-1, IEC 60601-1-2, and IEC 60601-1-4 and was found to meet all requirements. The Spectralis with Anterior Segment Module is a laser product of Class 1 according to 21 CFR §1040.10 and complies with IEC 60825-1.
In the comparative study, an ophthalmologist concluded equivalence between images from the Spectralis ASM and the RTVue predicate device. This study confirmed the ability of the Spectralis ASM to image and view the anterior segment.
Key Metrics
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 886.1570 Ophthalmoscope.
(a)
Identification. An ophthalmoscope is an AC-powered or battery-powered device containing illumination and viewing optics intended to examine the media (cornea, aqueous, lens, and vitreous) and the retina of the eye.(b)
Classification. Class II (special controls). The device, when it is an AC-powered opthalmoscope, a battery-powered opthalmoscope, or a hand-held ophthalmoscope replacement battery, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 886.9.
0
Image /page/0/Picture/1 description: The image shows a handwritten string of characters enclosed in a circle. The characters appear to be "K 113129". The writing is in black ink on a white background. The circle encompasses all the characters.
Page 1 / 2
510(k) Summary of Safety and Effectiveness
Manufacturer and Submitter
| Company Name: | Heidelberg Engineering GmbH |
|---|---|
| Company Address: | Tiergartenstrasse 15 |
| 69121 Heidelberg, Germany | |
| phone: +49 / 6221 / 64 643 0 | |
| fax: +49 / 6221 / 64 63 62 | |
| Contact Person: | Dr. Gerhard Zinser |
| Date Summary Prepared: | September 13, 2011 |
Device
| Trade/Device Name: | Spectralis Anterior Segment Module |
|---|---|
| Common/Usual Name: | Optical Coherence Tomograph |
| Classification Name: | Ophthalmoscope, AC-powered |
| Regulation Number: | 21 CFR 886.1570 |
| Product Code: | OBO, MYC |
| Classification Panel: | Ophthalmic |
| Classification: | Class II |
Substantial Equivalence
The Heidelberg Spectralis with Anterior Segment Module is substantially equivalent to the Optovue RTVue 100/CA (K071250), which is technologically similar devices for anterior segment imaging. A second predicate device is chosen, the Heidelberg Spectralis HRA+OCT (K101223) because it is the "parent" device to the Spectralis ASM.
Device Description
The Spectralis Anterior Segment Module (Spectralis ASM) is an accessory to the Spectralis HRA+OCT device cleared under K101223. The Spectralis HRA+OCT is a diagnostic device for imaging the human eye and for aiding in the assessment and management of various diseases of the posterior segment of the eye. Addition of the Spectralis ASM provides the user the additional ability to image and examine the anterior segment of the eye using simultaneous OCT and infrared reflectance imaging with OCT B-scan lengths of 8 mm, 11 mm, and 16 mm. Available OCT scan patterns are single line scans and volume scans.
Intended Use/Indications for Use
The Spectralis Anterior Segment Module is an accessory to the Spectralis HRA+OCT, and is indicated for imaging the anterior segment of the eye.
Substantial Equivalence Analysis
Analysis of the intended use of the predicate devices and the Spectralis ASM has led to the conclusion of substantial equivalence. The new device is similar to the predicate device in the use and ability to image and view the anterior segment of the eye. The Intended Use of the new device does not include the measurement of ocular structures of the eye, and this difference does not affect the use of the Spectralis ASM for viewing the same ocular structures as the predicate.
1
K 113129
Spectralis ASM has been demonstrated to perform as intended and has been shown to be substantially equivalent to the RTVue predicate device for viewing ocular structures of the eye. The technology characteristics of the new device when used with the Spectralis HRA+OCT (parent product) are similar to the RTVue predicate in design, materials and energy source, as both the new device and the RTVue auxiliary lens adapter are anterior lens accessories that are used together with the parent product to view the anterior segment of the eye.
Performance - Nonclinical
Bench Testing
The Spectralis HRA+OCT has been tested according to IEC 60601-1, IEC 60601-1-2, and IEC 60601-1-4 and was found to meet all requirements. The Spectralis with Anterior Segment Module is a laser product of Class 1 according to 21 CFR §1040.10 and complies with IEC 60825-1.
Studies to Demonstrate Equivalence in Viewing the Anterior Segment
Side-by-side images of the anterior segment of the eye were compared between the Spectralis ASM and the predicate. Images from both eyes of 29 subjects (healthy eyes and eyes with pathology) were compared by an ophthalmologist using Spectralis ASM and RTVue, and equivalence between the images was concluded.
Conclusions
This study confirmed the ability of the Spectralis ASM to image and view the anterior segment. and the substantial equivalence of Spectralis ASM to the predicate device.
2
Image /page/2/Picture/1 description: The image shows the logo for the Department of Health & Human Services - USA. The logo features a stylized eagle with three wing-like shapes, representing health, human services, and well-being. The eagle is encircled by the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" in a circular arrangement.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002
Heidelberg Engineering GmbH c/o Mr. William Sammons Intertek Testing Services 2307 East Aurora Road, Unit B7 Twinsburg, Ohio 44087
NOV - 8 2011
Re: K113129
Trade/Device Name: Spectralis Anterior Segment Module (Spectralis ASM) Regulation Number: 21 CFR 886.1570 Regulation Name: Ophthalmoscope Regulatory Class: Class II Product Code: OBO, MYC Dated: October 21, 2011 Received: October 24, 2011
Dear Mr. Sammons:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA), You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. Iisting of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set
3
Page 2 - Mr. William Sammons
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours.
Keoia Alexander
Malvina B. Eydelman, M.D. Director Division of Ophthalmic, Neurological, and Ear. Nose and Throat Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
Image /page/4/Picture/0 description: The image shows a handwritten sequence of characters enclosed in an oval shape. The characters appear to be a combination of letters and numbers, specifically 'K 11 3 12 9'. The writing style is casual, and the oval shape seems to be drawn around the characters to highlight or group them together.
Indications for Use
510(k) Number (if knówn): K113129
Device Name: Spectralis Anterior Segment Module
Indications For Use:
The Spectralis Anterior Segment Module is an accessory to the Spectralis HRA+OCT, and is indicated for imaging the anterior segment of the eye.
Prescription Use X (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
(Division Sign-Off)
Division of Ophthalmic, Neurological and Ear,
Nose and Throat Devices
510(k) Number K113129